<- Go Home

Urologix, Inc.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States.

Market Cap

$21.00

Volume

35.5K

Cash and Equivalents

$492.0K

EBITDA

-$373.0K

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$5.7M

Profit Margin

47.13%

52 Week High

$0.00

52 Week Low

$0.00

Dividend

N/A

Price / Book Value

-0.00

Price / Earnings

-0.00

Price / Tangible Book Value

-0.00

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

-$874.0K

Return on Equity

80.78%

Return on Assets

-7.62

Cash and Short Term Investments

$492.0K

Debt

$5.3M

Equity

-$8.1M

Revenue

$12.0M

Unlevered FCF

$1.2M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches